Dual Antiplatelet versus Defibrinogenation Therapy in Acute Ischemic Stroke: a Parallel Randomized, Open-label, Multicenter, Prospective study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006826

Enrollment

Unknown

Registered

2015-07-28

Start date

2015-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Interventions

Double Anti-group:Clopidogrel and aspirin

Defibrase group:Batroxobin

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 40-80 years old; 2. Within 48 hours of onset; 3. large artery atherosclerotic disease because of cerebral infarction (DWI + MRA confirmed); 4. NIHSS =4); 5. blood pressure =3; 9. written informed consent.

Exclusion criteria

Exclusion criteria: 1. hemorrhagic stroke or mixing stroke, or other causes of acute stroke of unknown etiology; 2. Plan thrombolytic treatment of patients; 3. with severe infection or liver, kidney, hematopoietic system, the endocrine system and other serious diseases; 4. The history of stroke and left severe sequelae; 5. Fibrinogen <3.0; 6. Within 3 months who are participating in other clinical trials; 7. pregnant or lactating women; 8. treatment and rehabilitation of patients and their families to a negative attitude, not actively cooperate with the person; 9. The researchers believe that the other person is not suitable to participate in this trial.

Design outcomes

Primary

Measure	Time frame
Recurrent stroke;	—

Secondary

Measure	Time frame
NISHH;	—

Countries

China

Contacts

Public Contactchenhuisheng

chszh@aliyun.com+86 13352452086

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026